EPZM Key Statistics, Chart & Performance
The current stock price of EPZM is 1.47 USD. In the past month the price decreased by -0.68%. In the past year, price decreased by -72.78%.
EPZM Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to EPZM. When comparing the yearly performance of all stocks, EPZM is one of the better performing stocks in the market, outperforming 97.75% of all stocks.
EPZM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EPZM. EPZM has a bad profitability rating. Also its financial health evaluation is rather negative.
EPZM Financial Highlights
Over the last trailing twelve months EPZM reported a non-GAAP Earnings per Share(EPS) of -1.68. The EPS increased by 33.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -391.89% | ||
| ROA | -78.64% | ||
| ROE | N/A | ||
| Debt/Equity | -11.48 |
EPZM Forecast & Estimates
9 analysts have analysed EPZM and the average price target is 3.04 USD. This implies a price increase of 107% is expected in the next year compared to the current price of 1.47.
For the next year, analysts expect an EPS growth of 43.15% and a revenue growth 28.63% for EPZM
EPZM Ownership
EPZM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.96 | 398.827B | ||
| AMGN | AMGEN INC | 16.25 | 182.324B | ||
| GILD | GILEAD SCIENCES INC | 16.37 | 177.765B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.11 | 118.135B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.68 | 79.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.14 | 46.476B | ||
| INSM | INSMED INC | N/A | 33.518B | ||
| NTRA | NATERA INC | N/A | 31.422B | ||
| BIIB | BIOGEN INC | 12.01 | 25.931B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.38 | 20.594B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EPZM
Company Profile
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 250 full-time employees. The company went IPO on 2013-05-31. The firm is engaged in the treatment of people with cancer through the discovery, development, and commercialization of epigenetic medicines. The firm's lead product TAZVERIK (tazemetostat) is used for epithelioid sarcoma (ES), and follicular lymphoma (FL). Tazemetostat is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT), for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced ES not eligible for complete resection. The company is developing tazemetostat for lymphomas and B-cell malignancies, including B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma and others. Its advanced product candidate, EZM0414, is an oral inhibitor of the SETD2 HMT. The firm is assessing the use of tazemetostat for immuno-oncology-sensitive tumors, such as small cell lung cancer, prostate cancer, and others.
Company Info
EPIZYME INC
400 Technology Sq Ste 4
Cambridge MASSACHUSETTS 02139 US
CEO: Robert B. Bazemore
Employees: 250
Phone: 16172295872.0
EPIZYME INC / EPZM FAQ
What does EPZM do?
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 250 full-time employees. The company went IPO on 2013-05-31. The firm is engaged in the treatment of people with cancer through the discovery, development, and commercialization of epigenetic medicines. The firm's lead product TAZVERIK (tazemetostat) is used for epithelioid sarcoma (ES), and follicular lymphoma (FL). Tazemetostat is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT), for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced ES not eligible for complete resection. The company is developing tazemetostat for lymphomas and B-cell malignancies, including B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma and others. Its advanced product candidate, EZM0414, is an oral inhibitor of the SETD2 HMT. The firm is assessing the use of tazemetostat for immuno-oncology-sensitive tumors, such as small cell lung cancer, prostate cancer, and others.
Can you provide the latest stock price for EPIZYME INC?
The current stock price of EPZM is 1.47 USD. The price decreased by -1.34% in the last trading session.
What is the dividend status of EPIZYME INC?
EPZM does not pay a dividend.
What is the ChartMill rating of EPIZYME INC stock?
EPZM has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for EPIZYME INC?
EPIZYME INC (EPZM) operates in the Health Care sector and the Biotechnology industry.
What is the expected growth for EPZM stock?
The Revenue of EPIZYME INC (EPZM) is expected to grow by 28.63% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is EPIZYME INC worth?
EPIZYME INC (EPZM) has a market capitalization of 247.44M USD. This makes EPZM a Micro Cap stock.